What is the target of Vandetanib?

Vandetanib is an oral multi-target tyrosine kinase inhibitor. Its main targets include vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR) and RET proto-oncogene. These targets play a central role in the growth and metastasis of medullary thyroid cancer (thyroid cancer) and other tumor types. By blockingVEGFR, vandetanib can inhibit tumor angiogenesis and reduce tumor blood supply, thereby inhibiting tumor cell proliferation and metastasis risk. EGFR inhibition can interfere with cell proliferation and growth signaling pathways, further inhibiting tumor development. Suppression of the RET proto-oncogene targets patients with RET mutations and blocks the abnormal signaling pathways driven by them. This is the core value of vandetanib in molecular targeted therapy.

At the molecular level, vandetanib competitively inhibitsATP binding site, preventing the target protein from being activated, thereby blocking downstream signaling. This mechanism not only limits the proliferation of tumor cells, but also reduces the support for angiogenesis in the tumor microenvironment, placing tumors in an unfavorable growth state. At the same time, vandetanib's multi-target mode of action improves its clinical scope of application, and it also has a certain effect on patients with multiple signaling pathway abnormalities.

In addition, vandetanib's targeting selectivity makes it relatively less toxic to healthy tissues. Common clinical adverse reactions mainly include rash, hypertension, diarrhea and electrocardiogram changes. By regularly monitoring blood pressure, heart rate and laboratory indicators, adverse drug events can be effectively managed and treatment safety ensured. In the future, with in-depth research on targeted drugs, the application potential of vandetanib in personalized precision treatment will be further expanded, providing a reliable long-term management solution for patients with RET mutations.

Reference materials:https://www.drugs.com/caprelsa.html